La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Ensysce Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Ensysce Biosciences..

Ensysce Biosciences (NASDAQ:ENSC) Azioni, Catena delle Opzioni

Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

Raymond James analyst Brian Peterson maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Outperform and lowers the price target from $48 to $43.

News

Price Target

Analyst Ratings

BRZE

Raymond James Maintains Outperform on Braze, Lowers Price Target to $43

Oppenheimer analyst Ittai Kidron maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $225 to $250.

SNOW

Oppenheimer Maintains Outperform on Snowflake, Raises Price Target to $250

Macro Economic Events

Economics

Federal Reserve

Live On CNBC, Fed's Harker Says Sees Steadiness In 'Solid' Latest Job Data; Much Of Tariff Impacts Yet To Be Felt; Fed Interest Rate Policy Is Modestly Restrictive; Now Is Time For Fed To Hold Steady And Watch Data

Oppenheimer analyst Ittai Kidron maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $290 to $345.

Oppenheimer Maintains Outperform on Zscaler, Raises Price Target to $345

Trading Ideas

BRLS

Borealis Foods Shares Halted On Circuit Breaker To The Downside, Stock Now Up 80%

WIIM

CYCU

Cycurion shares are trading lower after the company reported a Q1 EPS miss.

Oppenheimer analyst Leland Gershell initiates coverage on Climb Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLYM#NASDAQ">CLYM</a>) with a Outperform rating and announces Price Target of $10.

Initiation

CLYM

Oppenheimer Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $10

Insider Trades

Abacus Global Management Form4 Filing Shows President Kevin Scott Kirby Bought 86,207 Shares At An Average Price Of $5.77/Share; President Sean McNealy Bought 86,207 Shares At An Average Price Of $5.77/Share

Oppenheimer analyst Brian Schwartz maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Outperform and lowers the price target from $51 to $44.

Oppenheimer Maintains Outperform on Braze, Lowers Price Target to $44

NVNO

enVVeno Medical shares are trading higher after the company announced its interim two-year follow-up data on the VenoValve trial.

Abacus Global Management Form4 Filing Shows CFO William Hugh McCauley Bought 33,000 Shares At An Average Price Of $5.82/Share

JPMorgan analyst Doug Anmuth reiterated the Overweight rating on Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>),<a href="https://www.benzinga.com/quote/CHWY/analyst-ratings" target="_blank" rel="noreferrer noopener"> with a price target of $36.</a>
The company will report fiscal first quarter 2025 financial results before the market <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45316009/chewy-announces-fiscal-first-quarter-2025-financial-results-conference-call" rel="noreferrer noopener">opens on Wednesday, June 11.</a>
According to Anmuth, investors are anticipating an upside to Chewy's Q1 net sales guidance of $3.06 billion–$3.09 billion and see the company raising its FY25 outlook for net sales of $12.30 billion–$12.45 billion and adjusted EBITDA margins of 5.4%–5.7%.
Anmuth maintains a bullish view on Chewy, citing its category leadership, rising profitability, and push to diversify revenue through high-margin segments like pharmacy (now at $1 billion TTM), international expansion, and Sponsored Ads.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45630622/chwy-stock-short-interest-contrarian-trade" rel="noreferrer noopener">Options Corner: A Contrarian Case Builds As Traders Short Chewy Ahead Of Earnings</a>
He notes Chewy is seen as a defensive name, with over 80% of sales coming from Autoship customers, which he sees as a major edge supporting revenue visibility and strong unit economics.
He forecasts net customer adds of 104K sequentially in the first quarter of FY25 and 421K year over year for the full year.
SimilarWeb shows the company&#8217;s web traffic rose 4% year over year in the first quarter (down from 13% in the fourth quarter), with a pickup in May, while Bloomberg points to improving trends into the second quarter.
He estimates 6% year-over-year net sales growth for the first quarter and 3% for FY25—figures he considers may be conservative.
Anmuth sees profitability supported by ads, mix, automation, scale, and cost control, projecting a 5.4% adjusted EBITDA margin (+59bps year over year) and $524M in FCF (+16% year over year).
Price Action: CHWY shares are trading higher by 1.5% to $48.19 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45818750/docusign-posts-beat-and-raise-quarter-stock-tanks-almost-20" target="_blank" rel="noreferrer noopener">DocuSign Posts Beat-And-Raise Quarter; Stock Tanks Almost 20%</a></li>
</ul>
Photo: Briana Hunter/Shutterstock

Equities

Markets

General

CHWY

Chewy's Loyalty Engine, $1B Pharmacy Business Have JPMorgan Staying Bullish Before Q1

iPower shares are trading higher after the company announced the formation of United Package NV LLC.

<h3>Gainers</h3>
<ul>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) stock moved upwards by 44.6% to $1.75 during Friday's regular session. The market value of their outstanding shares is at $186.4 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) stock moved upwards by 31.23% to $8.85. The market value of their outstanding shares is at $35.5 million. The company's, Q1 earnings came out yesterday. </li>
<li>iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) shares moved upwards by 16.56% to $3.9. The company's market cap stands at $119.6 million. </li>
<li>GoPro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRO#NASDAQ">GPRO</a>) shares moved upwards by 15.87% to $0.8. The market value of their outstanding shares is at $125.2 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) stock rose 15.74% to $6.47. The company's market cap stands at $330.7 million. The company's, Q3 earnings came out today. </li>
<li>Red Robin Gourmet Burgers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) shares increased by 15.15% to $6.99. The market value of their outstanding shares is at $123.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) stock fell 29.1% to $5.0 during Friday's regular session. The market value of their outstanding shares is at $117.1 million. </li>
<li>Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) shares fell 24.89% to $2.72. The company's market cap stands at $758.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares fell 22.13% to $0.27. The market value of their outstanding shares is at $6.5 million. </li>
<li>Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) stock declined by 20.18% to $264.05. The company's market cap stands at $33.0 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) shares fell 15.08% to $23.5. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares decreased by 13.32% to $7.03. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CHGG

GIII

GPRO

IRBT

JDZG

LULU

MULN

RENT

RRGB

WOOF

YSXT

12 Consumer Discretionary Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) stock rose 85.8% to $8.71 during Friday's regular session. The company's market cap stands at $606.9 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares rose 54.86% to $0.79. The market value of their outstanding shares is at $5.9 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares rose 48.68% to $2.26. The market value of their outstanding shares is at $3.3 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock moved upwards by 39.16% to $1.86. The company's market cap stands at $48.5 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock moved upwards by 38.76% to $7.96. The market value of their outstanding shares is at $217.4 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 29.87% to $0.05. As per the news, the Q1 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares fell 29.0% to $21.74 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock fell 24.62% to $2.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 15.17% to $1.29. The market value of their outstanding shares is at $132.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 15.1% to $0.51. The company's market cap stands at $12.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares fell 13.4% to $3.0. The company's market cap stands at $4.4 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 13.39% to $0.53. The market value of their outstanding shares is at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAY

BJDX

BSGM

CYCC

EVOK

NCNA

NUWE

PHAT

SCNI

SXTC

VERA

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) shares rose 36.5% to $7.1 during Friday's regular session. The company's market cap stands at $150.1 million. As per the press release, Q2 earnings came out today. </li>
<li>Byrna Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) stock rose 24.16% to $32.99. The market value of their outstanding shares is at $747.7 million. </li>
<li>NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) stock moved upwards by 21.81% to $2.62. The market value of their outstanding shares is at $203.5 million. </li>
<li>Palladyne AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) stock rose 20.83% to $9.95. The market value of their outstanding shares is at $355.1 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) stock rose 17.45% to $1.25. The market value of their outstanding shares is at $17.3 million. </li>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) stock moved upwards by 17.42% to $4.11. The market value of their outstanding shares is at $32.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) shares decreased by 80.0% to $0.27 during Friday's regular session. The company's market cap stands at $14.9 million. </li>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) stock declined by 70.29% to $2.93. The market value of their outstanding shares is at $49.9 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock declined by 31.4% to $0.49. The company's market cap stands at $8.5 million. </li>
<li>Concrete Pumping Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBCP#NASDAQ">BBCP</a>) stock decreased by 17.64% to $5.84. The company's market cap stands at $309.8 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) stock fell 14.74% to $43.7. The company's market cap stands at $2.7 billion. As per the press release, Q2 earnings came out today. </li>
<li>ZJK Industrial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) stock fell 13.21% to $4.69. The market value of their outstanding shares is at $287.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBCP

BYRN

FCEL

MWYN

Nuveen Insured California Premium Fund Ii

NPWR

PDYN

UAVS

ZBAI

ZONE

12 Industrials Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares moved upwards by 34.8% to $0.62 during Friday's regular session. The company's market cap stands at $25.7 million. </li>
<li>Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) stock rose 29.44% to $8.44. The market value of their outstanding shares is at $209.5 million. </li>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares increased by 29.41% to $55.0. The company's market cap stands at $1.2 billion. </li>
<li>TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) stock rose 18.68% to $20.11. The market value of their outstanding shares is at $503.0 million. </li>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock increased by 17.77% to $22.59. The market value of their outstanding shares is at $417.1 million. </li>
<li>TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) stock rose 16.31% to $4.46. The company's market cap stands at $1.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Global Engine Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLE#NASDAQ">GLE</a>) stock decreased by 22.2% to $1.59 during Friday's regular session. The company's market cap stands at $29.1 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) stock declined by 18.2% to $3.08. The company's market cap stands at $4.0 million. </li>
<li>Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) shares fell 17.92% to $76.26. The market value of their outstanding shares is at $15.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock declined by 16.67% to $1.35. The company's market cap stands at $588.9 million. </li>
<li>Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) stock decreased by 15.55% to $30.49. The market value of their outstanding shares is at $3.1 billion. The company's, Q1 earnings came out yesterday. </li>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) stock fell 10.71% to $0.33. The market value of their outstanding shares is at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNAI

DGNX

DOCU

FOXO

GRRR

Next Technology Holding Inc. - Ordinary Shares

NXTT

OBLG

TSSI

UMAC

WULF

12 Information Technology Stocks Moving In Friday's Intraday Session

Northland Capital Markets analyst Ted Jackson downgrades Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) from Outperform to Market Perform and lowers the price target from $100 to $80.

Downgrades

Northland Capital Markets Downgrades Toro to Market Perform, Lowers Price Target to $80

Citigroup analyst Filippo Falorni maintains Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Neutral and lowers the price target from $35 to $28.

BF/B

Citigroup Maintains Neutral on Brown-Forman, Lowers Price Target to $28

Mizuho analyst Vijay Rakesh maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Outperform and raises the price target from $300 to $310.

AVGO

Mizuho Maintains Outperform on Broadcom, Raises Price Target to $310

Press Releases

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Earnings

Ensysce Biosciences Reports First Quarter 2025 Financial Results

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Comments

Ensysce Biosciences

Ensysce Biosciences (ENSC) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO